Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Dash0 | $9,500,000 | (Nov 5, 2024)
Resalis Therapeutics
Italy
- Turin, Piedmont
- 08/01/2024
- Pre Series A
- $10,952,000
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.
The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.
Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.
- Industry Biotechnology Research
- Website https://www.resalistherapeutics.com/
- LinkedIn https://www.linkedin.com/company/resalistherapeutics/about/
Related People
Alessandro TonioloFounder
Italy -
ND
20 years experience with life science and pharmaceutical business, from drug development to leading marketing and sales teams for top pharma and biotech companies in Oncology, Immunology, Rheumatology, Respiratory, Metabolic Diseases, Rare Diseases, Dermatology, Hematology.
Managed important brands such as Cosentyx, Enbrel, Xolair, Erbitux, Sutent, Replagal and many others at Local, Regional and Global levels.
Focused on creating the right environment for breakthrough innovation and growth
Miros | $6,535,520 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Inquis Medical, Inc. | $40,000,000 | (Nov 5, 2024)
CrossBridge Bio | $10,000,000 | (Nov 5, 2024)